Discovery of traditional Chinese medicine monomers and their synthetic intermediates, analogs or derivatives for battling P-gp-mediated multi-drug resistance

被引:40
作者
Ma, Xiaodong [1 ,2 ]
Hu, Mengqi [1 ]
Wang, Hao [3 ]
Li, Jiaming [1 ,2 ]
机构
[1] Anhui Univ Chinese Med, Sch Pharm, Hefei 230031, Anhui, Peoples R China
[2] Anhui Acad Chinese Med, Dept Med Chem, Hefei 230031, Anhui, Peoples R China
[3] Univ Sci & Technol China, Dept Clin Lab, Affiliated Hosp 1, Hefei 230001, Anhui, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
MDR; Cancer chemotherapy; P-gp inhibitors; TCM monomers; Structural analogs and derivatives; COLON-CANCER CELLS; NF-KAPPA-B; NITRIC-OXIDE; IN-VIVO; BIOLOGICAL EVALUATION; PROSTATE-CANCER; BREAST-CANCER; GLYCOPROTEIN INHIBITORS; THIOREDOXIN REDUCTASE; BIFENDATE DERIVATIVES;
D O I
10.1016/j.ejmech.2018.09.061
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
P-glycoprotein (P-gp)-mediated multi-drug resistance (MDR) is a well-documented and predominant phenotype hampering patients' response to cancer chemotherapy. Although the past several decades have witnessed the development of three generations of P-gp inhibitors, they have not lived up to the high expectations owing to their drawbacks, as exemplified by limited efficacy, drug-drug interactions (DDIs) and severe untoward reactions. The discovery of artemisinin is a testimony of the importance of traditional Chinese medicine (TCM) in innovative drug discovery. In search for a new generation of chemo-sensitizers, P-gp modulators originated from TCM have attracted increasing concern in the research community. In addition to identify TCM monomers or their synthetic intermediates as P-gp modulators, massive medicinal chemistry efforts have been made in discovering promising structural analogs and derivatives of them. Among these, compounds with dual role both as P-gp inhibitor and cytotoxic agent have continuously emerged. Hence, in this article, we will mainly enumerate the representative work conducted in the discovery of TCM monomers and their synthetic intermediates, analogs or derivatives as reversers of P-gp-mediated MDR. (C) 2018 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:381 / 392
页数:12
相关论文
共 125 条
[1]   Discovery of New Monocarbonyl Ligustrazine-Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer [J].
Ai, Yong ;
Zhu, Bin ;
Ren, Caiping ;
Kang, Fenghua ;
Lo, Jinlong ;
Huang, Zhangjian ;
Lai, Yisheng ;
Peng, Sixun ;
Ding, Ke ;
Tian, Jide ;
Zhang, Yihua .
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (05) :1747-1760
[2]   Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding [J].
Aller, Stephen G. ;
Yu, Jodie ;
Ward, Andrew ;
Weng, Yue ;
Chittaboina, Srinivas ;
Zhuo, Rupeng ;
Harrell, Patina M. ;
Trinh, Yenphuong T. ;
Zhang, Qinghai ;
Urbatsch, Ina L. ;
Chang, Geoffrey .
SCIENCE, 2009, 323 (5922) :1718-1722
[3]   Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells [J].
Anuchapreeda, S ;
Leechanachai, P ;
Smith, MM ;
Ambudkar, SV ;
Limtrakul, P .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (04) :573-582
[4]   Analysis of GSTP1-1 polymorphism using real-time polymerase chain reaction [J].
Ballerini, S ;
Bellincampi, L ;
Bernardini, S ;
Iori, R ;
Cortese, C ;
Federici, G .
CLINICA CHIMICA ACTA, 2003, 329 (1-2) :127-132
[5]   Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin [J].
Barthomeuf, C ;
Grassi, J ;
Demeule, M ;
Fournier, C ;
Boivin, D ;
Béliveau, R .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (02) :173-181
[6]   Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells [J].
Beevers, Christopher S. ;
Li, Fengjun ;
Liu, Lei ;
Huang, Shile .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (04) :757-764
[7]  
Berggren M, 1996, ANTICANCER RES, V16, P3459
[8]   Principles in Redox Signaling: From Chemistry to Functional Significance [J].
Bindoli, Alberto ;
Rigobello, Maria Pia .
ANTIOXIDANTS & REDOX SIGNALING, 2013, 18 (13) :1557-1593
[9]   P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives [J].
Binkhathlan, Ziyad ;
Lavasanifar, Afsaneh .
CURRENT CANCER DRUG TARGETS, 2013, 13 (03) :326-346
[10]   Novel therapeutic applications of nitric oxide donors in cancer: Roles in chemo- and immunosensitization to apoptosis and inhibition of metastases [J].
Bonavida, Benjamin ;
Baritaki, Stavroula ;
Huerta-Yepez, Sara ;
Vega, Mario I. ;
Chatterjee, Devasis ;
Yeung, Kam .
NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2008, 19 (02) :152-157